India, known as the “Pharmacy of the World,” supplies over 20% of the global generic medicine market by volume. But with this position comes a critical responsibility — maintaining rigorous manufacturing quality standards. For international buyers, verifying Good Manufacturing Practice (GMP) compliance of Indian suppliers is not optional; it is a regulatory and safety necessity. This guide explains how to verify GMP compliance in 2026, following India’s landmark Schedule M reforms.
🔬 What Is GMP and Why Does It Matter for Indian Generics?
Good Manufacturing Practice (GMP) is a system of quality assurance that ensures pharmaceutical products are consistently produced and controlled according to quality standards. It covers all aspects of production — from raw materials, premises, and equipment to staff training, hygiene, and record-keeping.
In India, GMP compliance is governed by Schedule M of the Drugs and Cosmetics Act, 1940. In December 2023, the Indian government notified revised Schedule M standards aligned with WHO-GMP requirements. These norms were enforced from January 1, 2026, as confirmed by the Drug Controller General of India (DCGI) — a landmark reform that raised the bar for all drug manufacturers in the country (as reported by ETPharma, December 2025; The New Indian Express, November 2025).
The crackdown follows a series of incidents involving contaminated cough syrups linked to child deaths in Gambia, Uzbekistan, and other countries, which severely damaged India’s pharmaceutical reputation globally. As reported by India Today (November 2025), the DCGI put manufacturers on notice: “Upgrade by January 1 or shut shop.”
📋 Step 1: Understand the Revised Schedule M Requirements
Before you can verify compliance, you need to know what Indian manufacturers are now expected to meet. The revised Schedule M (2023) introduced major upgrades:
- WHO-GMP alignment: Manufacturing facilities must now meet international GMP standards, not just Indian minimum requirements
- Pharmaceutical Quality System (PQS): Companies must implement a documented quality system covering all production stages
- Validation requirements: Mandatory process validation, cleaning validation, and analytical method validation
- Stability testing: Extended stability data requirements aligned with ICH guidelines
- Water system qualification: Strict pharmacopoeial standards for purified water and Water for Injection (WFI)
- HVAC qualification: Clean room classification and environmental monitoring for sterile products
- Product recalls: Formal recall procedures and mock recall exercises
Large manufacturers (turnover > ₹250 crore) were given until July 2024, while small and medium enterprises (MSMEs) had until January 1, 2026 — a deadline the health ministry decided not to extend, despite industry pleas (as reported by Business Standard, December 2025; ETPharma, December 2025).
🔍 Step 2: Verify CDSCO Manufacturing License
Every pharmaceutical manufacturer in India must hold a valid manufacturing license issued by the state drug controller under the Drugs and Cosmetics Act. Here is how to verify it:
- Request the license number from the supplier — it begins with “Mfg. Lic. No.” followed by a state code (e.g., MH for Maharashtra, GJ for Gujarat, KA for Karnataka)
- Cross-check with the state drug authority — each state maintains a register of licensed manufacturers. Some states (Gujarat, Maharashtra, Telangana) provide online verification portals
- Verify the address — the license specifies the exact manufacturing address. Ensure it matches the supplier’s declared facility
- Check license类别 — licenses specify which dosage forms are approved (tablets, capsules, injectables, liquids, etc.)
- Confirm renewal status — manufacturing licenses must be renewed periodically. An expired license is a major red flag
Buyers should note that a valid manufacturing license alone does not guarantee GMP compliance — it is the baseline requirement, not the full certification.
🏭 Step 3: Check WHO-GMP Certification Status
With the revised Schedule M now aligned with WHO-GMP standards, WHO-GMP certification has become the industry benchmark. Here is how to verify it:
- Request the WHO-GMP certificate — ask the supplier for a copy of their current WHO-GMP certificate issued by the state drug controller
- Check the issue date and validity — WHO-GMP certificates in India are typically valid for 3 years. An expired or recently expired certificate requires investigation
- Verify via CDSCO — the Central Drugs Standard Control Organisation maintains records of WHO-GMP certified manufacturers. Request verification through CDSCO’s zonal offices
- Cross-reference product-specific approvals — a manufacturer may have WHO-GMP for some product categories but not others. Ensure your specific product line is covered
- Check for COPP (Certificate of Pharmaceutical Product) — issued by CDSCO for individual products, this confirms the product is manufactured in a GMP-compliant facility and is essential for import registration in many countries
As reported by ETPharma (February 2026), CDSCO has announced plans to outsource GMP audits to agencies certified by the Quality Council of India (QCI) and onboard 1,500 subject experts to strengthen regulatory capacity — a move that will make third-party GMP verification more systematic. This initiative was also covered by Business Standard (February 2026) and IndiaMedToday (February 2026).
🛡️ Step 4: Verify Inspection and Audit Records
India’s drug regulatory apparatus has significantly intensified inspections. Key developments that buyers should track:
- CDSCO outsourced GMP audits: As of February 2026, CDSCO is outsourcing GMP audits to QCI-accredited agencies and expanding its scientific cadre by 1,500 experts (ETPharma, Business Standard, Feb 2026)
- Cough syrup crackdown: CDSCO audited nearly 90% of cough syrup manufacturers and served 850 CAPA (Corrective and Preventive Action) notices — a massive enforcement sweep (Medical Dialogues, February 2026)
- Himachal shutdowns: Approximately 10 pharmaceutical units in Himachal Pradesh closed or surrendered their licenses due to inability to meet GMP requirements (ETPharma, January 2026)
- State-level inspections: DCGI directed state drug controllers to begin inspections under revised Schedule M norms immediately (ETPharma, The New Indian Express, November 2025)
For international buyers: Request inspection reports from the manufacturer. Reputable suppliers who undergo regular audits (by CDSCO, WHO, USFDA, or third-party agencies) will share their compliance records. If a manufacturer is reluctant to share inspection history, treat that as a significant red flag.
🌍 Step 5: Engage Verified Distributors (IMSDA Member Directory)
The most reliable way to source from GMP-compliant Indian manufacturers is to work with verified, established distributors who have already performed the due diligence. The Indian Medicine Manufacturers and Sellers & Distributors Association (IMSDA) maintains a directory of verified member distributors committed to ethical trade and quality compliance.
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory. These members are vetted for regulatory compliance and can connect you with GMP-certified manufacturers directly.
When evaluating a distributor or intermediary:
- Confirm they hold a valid wholesale drug license
- Request their manufacturer audit reports
- Check their track record with international clients
- Verify they can provide COPP and other export documentation
✅ Practical Checklist for Verifying GMP Compliance
Use this 10-point checklist when evaluating an Indian generic medicine manufacturer:
- ✅ Valid CDSCO manufacturing license — verify with state drug authority
- ✅ Current WHO-GMP certificate — check issue date and product scope
- ✅ COPP available — for individual products (essential for export)
- ✅ Revised Schedule M compliance — confirmed post-January 2026 status
- ✅ Inspection records — shareable audit reports from CDSCO, WHO, or third-party agencies
- ✅ No NSQ (Not of Standard Quality) alerts — check CDSCO monthly NSQ lists for the manufacturer’s products
- ✅ Stability data — ICH-compliant stability studies for your products of interest
- ✅ Quality management system — documented PQS with change control, deviation, CAPA processes
- ✅ Reference customers — verifiable international buyers who can vouch for product quality
- ✅ Transparent communication — willingness to share documentation and answer technical questions
⚠️ Red Flags to Watch For
Be cautious if the supplier exhibits any of these warning signs:
- Unable or unwilling to provide a WHO-GMP certificate
- Manufacturing license is expired or about to expire
- Multiple product entries in CDSCO’s NSQ (Not of Standard Quality) alerts
- Refuses to share inspection reports or audit findings
- Products priced significantly below market average (quality has a cost)
- Facility address on license does not match communication address
- No physical premises or office presence
- Claims certifications without providing verifiable certificate numbers
🔮 The Future of GMP Oversight in India
The trajectory of GMP enforcement in India is clear — standards are rising and compliance is being enforced. Key developments to watch include:
- Outsourced GMP audits to QCI-accredited agencies (announced February 2026) will increase the frequency and quality of facility inspections
- 1,500+ expert scientific cadre being onboarded by CDSCO will strengthen regulatory review capacity
- State-level inspection infrastructure is being upgraded with DCGI directives to enforce Schedule M strictly
- Export market pressure — importing countries (USFDA, EMA, WHO) continue to scrutinize Indian generics, driving voluntary compliance improvements
- Industry consolidation — MSMEs unable to meet GMP standards may close or be acquired, raising the average quality baseline
For international buyers, this means due diligence is evolving from “nice to have” to “must-have.” The manufacturers that survive and thrive under India’s new GMP regime are exactly the partners you want for reliable, high-quality generic medicine supply.
🤝 Final Thoughts
Verifying GMP compliance of Indian generic medicine manufacturers requires a systematic approach — checking licenses, certifications, inspection records, and market reputation. The revised Schedule M enforcement from January 2026 has made this process easier by raising the baseline standard for all manufacturers. For buyers who need a shortcut to reliable partners, the IMSDA’s verified member directory offers a curated list of compliant distributors who have already passed quality and regulatory checks.
For more information, contact IMSDA at contact@indiamedicine.org.